Groupe d'Etude en Oncologie du Quebec

Title	A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Protocole ID	MK-9999-02A
ClinicalTrials.gov ID	NCT06428409
Cancer Type(s)	Colon and Rectum Hepatic Ducts Pancreas
Phase	Phase I-II
Stage
Study Type	Clinical
Drug	Sacituzumab tirumotecan seul ou avec de la chimiothérapie
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
City
Principal Investigator	Dr. Francine Aubin
Coordinator	Adeline Hamon 514-890-8000 poste 30737
Status	Recruiting
Activation Date
Eligibility Criteria	The main inclusion criteria include but are not limited to the following: Has one of the following cancers: Unresectable or metastatic colorectal cancer Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) Advanced and/or unresectable biliary tract cancer (BTC) Has received prior therapy for the cancer Has recovered from any side effects due to previous cancer treatment
Exclusion Criteria	The main exclusion criteria include but are not limited to the following: History of severe eye disease Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Groupe d'étude en oncologie du Québec